Chest
-
COPD QVA149 PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: Sustained bronchodilation is thought to contribute to the reduction in exacerbations in patients with chronic obstructive pulmonary disease (COPD). Here we evaluate the effect of once-daily QVA149, a dual bronchodilator fixed-dose combination of indacaterol and glycopyrronium, on lung function and exacerbation rates in comparison with tiotropium. ⋯ Jadwiga Wedzicha: Consultant fee, speaker bureau, advisory committee, etc.: JW has received speaking fee and/or for advisory boards from GlaxoSmithKline, AstraZeneca, Novartis, Bayer, Boehringer Ingelheim, Nycomed. Chiesi and Respifor as well as travel reimbursements from Boehringer Ingelheim. JW has received research grants from GlaxoSmithKline, AstraZeneca, Chiesi and Novartis. Angel FowlerTaylor: Employee: Novartis employee Peter D'Andrea: Employee: Novartis employee Christie Arrasate: Employee: Novartis employee Hungta Chen: Employee: Novartis employee Donald Banerji: Employee: Novartis employee The following authors have nothing to disclose: Joachim FickerNo Product/Research Disclosure Information.
-
OSA PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: CPAP Compliance in OSAHS is low all over the world. Studies evaluating compliance related issues in Indian patients using CPAP are scarce. ⋯ The following authors have nothing to disclose: Pallavi Periwal, Mir Ali, Deepak TalwarNo Product/Research Disclosure Information.
-
OSA PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: The most suitable treatment for OSAS is the CPAP. However there are patients who don't tolerate it. A therapeutic not surgical alternative is MAD . It consists of a plastic rod which being introduced in dental arcades produces the advance of the jaw and indirectly the advance of the tongue, hyoid and suprahyoidea musculature. All this implies a space and permeability increase of the top airway. Our objective is to evaluate the efficiency of the MAD, Herbst type, as a treatment for OSAS. This evaluation will be carried out by means of clinic and functional variables. ⋯ The following authors have nothing to disclose: Maria Pavón, Estefania Luque, Jose María Benitez, Jesús Sánchez, Andrés Vega Arias, Teodoro MontemayorNo Product/Research Disclosure Information.
-
Pleural Disease/Pneumothorax PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: Primary spontaneous pneumothorax (PSP) occurs in patients with no clinically apparent underlying lung disease. Those aged less than 50 year with no significant smoking history are also included in this group according to the British Thoracic Society (BTS) pneumothorax management algorithm. There is paucity of data on treatment outcomes based on age criteria. We aimed to compare treatment outcomes including successful re-inflation rates in patients aged <30 and 31-50. ⋯ The following authors have nothing to disclose: Muhammad Ganaie, Shiva Bikmalla, Masood Khalil, Muhammad Afridi, Mohammed Haris, Imran HussainNo Product/Research Disclosure Information.
-
AsthmaSESSION TYPE: Slide PresentationsPRESENTED ON: Saturday, March 22, 2014 at 12:15 PM - 01:15 PMPURPOSE: Asthma is a heterogenous disease with distinct clinical phenotypes, including the exacerbation-prone phenotype. This subset of patients contributes to disproportionately high morbidity, mortality and healthcare utilization among all asthma patients. We aimed to investigate the factors that are associated with frequent asthma exacerbations in patients with severe asthma. ⋯ The following authors have nothing to disclose: Jessica Tan, Mariko Koh, Anthony Yii, Adrian ChanNo Product/Research Disclosure Information.